vs
ANI PHARMACEUTICALS INC（ANIP）与Mativ Holdings, Inc.（MATV）财务数据对比。点击上方公司名可切换其他公司
Mativ Holdings, Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.9倍（$463.1M vs $247.1M），Mativ Holdings, Inc.净利率更高（21.8% vs 11.1%，领先10.6%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 1.0%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $8.0M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs -3.8%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Mativ Holdings是一家全球特种材料制造商，主要生产高性能先进聚合物、无纺布、过滤解决方案及功能性涂层材料，服务医疗、工业、消费品、航空航天、能源等领域，业务遍及北美、欧洲及亚太地区。
ANIP vs MATV — 直观对比
营收规模更大
MATV
是对方的1.9倍
$247.1M
营收增速更快
ANIP
高出28.7%
1.0%
净利率更高
MATV
高出10.6%
11.1%
自由现金流更多
ANIP
多$21.1M
$8.0M
两年增速更快
ANIP
近两年复合增速
-3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $463.1M |
| 净利润 | $27.5M | $100.8M |
| 毛利率 | — | 18.8% |
| 营业利润率 | 14.1% | 2.2% |
| 净利率 | 11.1% | 21.8% |
| 营收同比 | 29.6% | 1.0% |
| 净利润同比 | 367.5% | 6620.0% |
| 每股收益（稀释后） | $1.14 | $1.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPMATV
| Q4 25 | $247.1M | $463.1M | ||
| Q3 25 | $227.8M | $513.7M | ||
| Q2 25 | $211.4M | $525.4M | ||
| Q1 25 | $197.1M | $484.8M | ||
| Q4 24 | $190.6M | $458.6M | ||
| Q3 24 | $148.3M | $498.5M | ||
| Q2 24 | $138.0M | $523.8M | ||
| Q1 24 | $137.4M | $500.2M |
净利润ANIPMATV
| Q4 25 | $27.5M | $100.8M | ||
| Q3 25 | $26.6M | $-3.2M | ||
| Q2 25 | $8.5M | $-9.5M | ||
| Q1 25 | $15.7M | $-425.5M | ||
| Q4 24 | $-10.3M | $1.5M | ||
| Q3 24 | $-24.2M | $-20.8M | ||
| Q2 24 | $-2.3M | $-1.4M | ||
| Q1 24 | $18.2M | $-28.0M |
毛利率ANIPMATV
| Q4 25 | — | 18.8% | ||
| Q3 25 | — | 19.3% | ||
| Q2 25 | — | 19.7% | ||
| Q1 25 | — | 15.0% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 18.8% | ||
| Q2 24 | — | 20.8% | ||
| Q1 24 | — | 16.8% |
营业利润率ANIPMATV
| Q4 25 | 14.1% | 2.2% | ||
| Q3 25 | 15.9% | 3.1% | ||
| Q2 25 | 6.6% | 3.8% | ||
| Q1 25 | 13.3% | -88.8% | ||
| Q4 24 | -2.3% | 0.6% | ||
| Q3 24 | -13.8% | 1.4% | ||
| Q2 24 | 3.7% | 2.0% | ||
| Q1 24 | 14.8% | -2.8% |
净利率ANIPMATV
| Q4 25 | 11.1% | 21.8% | ||
| Q3 25 | 11.7% | -0.6% | ||
| Q2 25 | 4.0% | -1.8% | ||
| Q1 25 | 8.0% | -87.8% | ||
| Q4 24 | -5.4% | 0.3% | ||
| Q3 24 | -16.3% | -4.2% | ||
| Q2 24 | -1.7% | -0.3% | ||
| Q1 24 | 13.2% | -5.6% |
每股收益（稀释后）ANIPMATV
| Q4 25 | $1.14 | $1.87 | ||
| Q3 25 | $1.13 | $-0.06 | ||
| Q2 25 | $0.36 | $-0.18 | ||
| Q1 25 | $0.69 | $-7.82 | ||
| Q4 24 | $-0.45 | $0.03 | ||
| Q3 24 | $-1.27 | $-0.38 | ||
| Q2 24 | $-0.14 | $-0.03 | ||
| Q1 24 | $0.82 | $-0.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $84.2M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $540.7M | $498.7M |
| 总资产 | $1.4B | $2.1B |
| 负债/权益比越低杠杆越低 | — | 2.07× |
8季度趋势，按日历期对齐
现金及短期投资ANIPMATV
| Q4 25 | $285.6M | $84.2M | ||
| Q3 25 | $262.6M | $97.1M | ||
| Q2 25 | $217.8M | $95.6M | ||
| Q1 25 | $149.8M | $84.0M | ||
| Q4 24 | $144.9M | $94.3M | ||
| Q3 24 | $145.0M | $162.2M | ||
| Q2 24 | $240.1M | $133.4M | ||
| Q1 24 | $228.6M | $128.9M |
总债务ANIPMATV
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
股东权益ANIPMATV
| Q4 25 | $540.7M | $498.7M | ||
| Q3 25 | $505.8M | $397.4M | ||
| Q2 25 | $436.8M | $416.6M | ||
| Q1 25 | $418.6M | $428.2M | ||
| Q4 24 | $403.7M | $858.5M | ||
| Q3 24 | $405.9M | $882.3M | ||
| Q2 24 | $455.8M | $898.0M | ||
| Q1 24 | $452.0M | $906.9M |
总资产ANIPMATV
| Q4 25 | $1.4B | $2.1B | ||
| Q3 25 | $1.4B | $2.0B | ||
| Q2 25 | $1.3B | $2.1B | ||
| Q1 25 | $1.3B | $2.1B | ||
| Q4 24 | $1.3B | $2.4B | ||
| Q3 24 | $1.3B | $2.6B | ||
| Q2 24 | $920.8M | $2.6B | ||
| Q1 24 | $914.5M | $2.7B |
负债/权益比ANIPMATV
| Q4 25 | — | 2.07× | ||
| Q3 25 | — | 2.63× | ||
| Q2 25 | — | 2.66× | ||
| Q1 25 | — | 2.67× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | — | 1.30× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $19.3M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $8.0M |
| 自由现金流率自由现金流/营收 | 11.8% | 1.7% |
| 资本支出强度资本支出/营收 | 0.5% | 2.4% |
| 现金转化率经营现金流/净利润 | 1.10× | 0.19× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $93.8M |
8季度趋势，按日历期对齐
经营现金流ANIPMATV
| Q4 25 | $30.4M | $19.3M | ||
| Q3 25 | $44.1M | $72.8M | ||
| Q2 25 | $75.8M | $57.6M | ||
| Q1 25 | $35.0M | $-15.9M | ||
| Q4 24 | $15.9M | $24.1M | ||
| Q3 24 | $12.5M | $37.6M | ||
| Q2 24 | $17.4M | $46.1M | ||
| Q1 24 | $18.3M | $-13.0M |
自由现金流ANIPMATV
| Q4 25 | $29.1M | $8.0M | ||
| Q3 25 | $38.0M | $66.7M | ||
| Q2 25 | $71.8M | $48.9M | ||
| Q1 25 | $32.5M | $-29.8M | ||
| Q4 24 | $13.5M | $2.0M | ||
| Q3 24 | $7.7M | $25.5M | ||
| Q2 24 | $13.0M | $37.4M | ||
| Q1 24 | $13.7M | $-25.1M |
自由现金流率ANIPMATV
| Q4 25 | 11.8% | 1.7% | ||
| Q3 25 | 16.7% | 13.0% | ||
| Q2 25 | 34.0% | 9.3% | ||
| Q1 25 | 16.5% | -6.1% | ||
| Q4 24 | 7.1% | 0.4% | ||
| Q3 24 | 5.2% | 5.1% | ||
| Q2 24 | 9.4% | 7.1% | ||
| Q1 24 | 10.0% | -5.0% |
资本支出强度ANIPMATV
| Q4 25 | 0.5% | 2.4% | ||
| Q3 25 | 2.7% | 1.2% | ||
| Q2 25 | 1.9% | 1.7% | ||
| Q1 25 | 1.3% | 2.9% | ||
| Q4 24 | 1.3% | 4.8% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 3.2% | 1.7% | ||
| Q1 24 | 3.3% | 2.4% |
现金转化率ANIPMATV
| Q4 25 | 1.10× | 0.19× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 16.07× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
